Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;24(6):993-1002.
doi: 10.1016/j.ajt.2024.02.013. Epub 2024 Feb 20.

Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma

Affiliations

Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma

Fiona O Zwald et al. Am J Transplant. 2024 Jun.

Abstract

Melanoma causes significant morbidity in solid organ transplant recipients (SOTRs). Melanomas diagnosed before transplantation can recur with intensive immunosuppression, but outcomes have not been well studied. We evaluated 901 non-Hispanic White SOTRs with a pretransplant melanoma identified using linked transplant and cancer registry data in the United States. Most pretransplant melanomas were invasive (60.7%), and the median time from diagnosis to transplantation was 5.1 years. After transplantation, 41 SOTRs developed a new invasive melanoma, corresponding to 9-fold increased risk compared with the general population (standardized incidence ratio, 9.2; 95% confidence interval [CI], 6.6-12). Twenty-two SOTRs died from melanoma after transplantation, corresponding to 52-fold increased risk (standardized mortality ratio, 52; 95% CI, 33-79). Risk factors for posttransplant melanoma included age at transplantation (adjusted hazard ratio [HR], 2.86; 95% CI, 1.24-6.60; for age 55+ vs <55 years) and maintenance immunosuppression with cyclosporine/azathioprine (adjusted HR, 2.53; 95% CI, 1.08-5.90). Melanoma mortality was strongly elevated after a posttransplant melanoma diagnosis (HR, 35.6; 95% CI, 14.0-90.4; adjusted for cyclosporine/azathioprine maintenance therapy and calendar year of transplantation). In conclusion, SOTRs with a pretransplant melanoma are at risk of adverse melanoma-related outcomes after transplantation. These findings support thorough dermatologic evaluation prior to transplantation and frequent posttransplant surveillance.

Keywords: immunosuppression; melanoma; solid organ transplantation.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

Figures

Figure 1
Figure 1
Kaplan-Meier curves depict the survival probability (i.e., 1 minus the probability of developing the event) for posttransplant invasive melanoma (blue line) and melanoma mortality (red line) among SOTRs with a pretransplant melanoma. Colored regions indicate 95% confidence bands. The numbers below the plot correspond to the number of people under follow-up at each 5-year landmark.

Similar articles

References

    1. Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernandez BY, Paddock L, Yanik EL, Lynch CF, Kasiske BL, Snyder J, Engels EA. Melanoma Risk and Survival among Organ Transplant Recipients. J Invest Dermatol. 2015;135(11):2657–65. - PMC - PubMed
    1. Shiels MS, Copeland G, Goodman MT, Harrell J, Lynch CF, Pawlish K, Pfeiffer RM, Engels EA. Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients. Cancer. 2015;121(12):2063–71. - PMC - PubMed
    1. Park CK, Dahlke EJ, Fung K, Kitchen J, Austin PC, Rochon PA, Chan AW. Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. J Am Acad Dermatol. 2020;83(3):754–61. - PubMed
    1. Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc. 2001;33(1–2):1830–1. - PubMed
    1. Penn I Malignant melanoma in organ allograft recipients. Transplantation. 1996;61(2):274–8. - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources